255 related articles for article (PubMed ID: 32356913)
21. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
24. Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease.
Metzner B; Welzel J; Müller TH; Casper J; Kimmich C; Petershofen EK; Renzelmann A; Rosien B; Thole R; Voss A; Willborn K; Köhne CH
Strahlenther Onkol; 2022 Jan; 198(1):39-46. PubMed ID: 34735577
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
Arcari A; Chiappella A; Spina M; Zanlari L; Bernuzzi P; Valenti V; Tani M; Marasca R; Cabras MG; Zambello R; Santagostino A; Ilariucci F; Carli G; Musto P; Savini P; Marino D; Ghio F; Gentile M; Cox MC; Vallisa D
Leuk Lymphoma; 2016 Aug; 57(8):1823-30. PubMed ID: 26666433
[TBL] [Abstract][Full Text] [Related]
26. A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma.
Shea L; Watkins MP; Wan F; Cashen AF; Wagner-Johnston ND; Jacoby MA; Abboud CN; Dipersio JF; Hurd DD; Jaglowski SM; Bartlett NL; Fehniger TA
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2223-2228. PubMed ID: 32829079
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Martín García-Sancho A; Baile M; Rodríguez G; Dlouhy I; Sancho JM; Jarque I; González-Barca E; Salar A; Espeso M; Grande C; Bergua J; Montes-Moreno S; Redondo A; Enjuanes A; Campo E; López-Guillermo A; Caballero D
Br J Haematol; 2023 Oct; 203(2):202-211. PubMed ID: 37485564
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
29. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
Padrnos L; Ernst B; Dueck AC; Kosiorek HE; Ginos BF; Toro A; Johnston PB; Habermann TM; Leis JF; Mikhael JR; Nowakowski GS; Colgan J; Porrata L; Ansell SM; Witzig TE; Reeder C
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):664-672.e2. PubMed ID: 30104176
[TBL] [Abstract][Full Text] [Related]
30. Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience.
Gaut D; Romero T; Oveisi D; Howell G; Schiller G
Hematol Oncol; 2020 Feb; 38(1):38-50. PubMed ID: 31674036
[TBL] [Abstract][Full Text] [Related]
31. Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective.
Reddy NM; Thieblemont C
Ann Oncol; 2017 Nov; 28(11):2680-2690. PubMed ID: 29045503
[TBL] [Abstract][Full Text] [Related]
32. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Duell J; Maddocks KJ; González-Barca E; Jurczak W; Liberati AM; De Vos S; Nagy Z; Obr A; Gaidano G; Abrisqueta P; Kalakonda N; André M; Dreyling M; Menne T; Tournilhac O; Augustin M; Rosenwald A; Dirnberger-Hertweck M; Weirather J; Ambarkhane S; Salles G
Haematologica; 2021 Sep; 106(9):2417-2426. PubMed ID: 34196165
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study.
Vose JM; Ganguly S; Bierman PJ; Bociek RG; Lunning M; Lyden L; Meza JL; Caimi PF; Armitage JO
Br J Haematol; 2023 Jul; 202(1):116-121. PubMed ID: 37096954
[TBL] [Abstract][Full Text] [Related]
35. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.
Castellino A; Chiappella A; LaPlant BR; Pederson LD; Gaidano G; Macon WR; Inghirami G; Reeder CB; Tucci A; King RL; Congiu A; Foran JM; Pavone V; Rivera CE; Spina M; Ansell SM; Cavallo F; Molinari AL; Ciccone G; Habermann TM; Witzig TE; Vitolo U; Nowakowski GS
Blood Cancer J; 2018 Nov; 8(11):108. PubMed ID: 30410035
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
Kim J; Cho J; Yoon SE; Kim WS; Kim SJ
Cancer Res Treat; 2023 Jul; 55(3):1031-1047. PubMed ID: 36915243
[TBL] [Abstract][Full Text] [Related]
39. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
Cox MC; Pelliccia S; Marcheselli L; Battistini R; Arcari A; Borza PA; Patti C; Casaroli I; di Landro F; Di Napoli A; Fabbri F; Caridi M; Tafuri A; Bocci G; Musuraca G
Invest New Drugs; 2019 Jun; 37(3):548-558. PubMed ID: 31028663
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Palazón-Carrión N; Martín García-Sancho A; Nogales-Fernández E; Jiménez-Cortegana C; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Salar-Silvestre A; Rodríguez-Abreu D; Gálvez-Carvajal L; Labrador J; Guirado-Risueño M; García-Domínguez DJ; Hontecillas-Prieto L; Espejo-García P; Fernández-Román I; Provencio-Pulla M; Sánchez-Beato M; Navarro M; Marylene L; Álvaro-Naranjo T; Casanova-Espinosa M; Sánchez-Margalet V; Rueda-Domínguez A; de la Cruz-Merino L
Clin Cancer Res; 2022 Sep; 28(17):3658-3668. PubMed ID: 35727601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
